Clinical and membranostabilizing effects of dimephosphone and prednizolone and/or cyclophosphamide in the treatment of active glomerulonephritis

The dynamics of clinicolaboratory indices and destabilization of membranes in patients with active glomerulonephritis is studied in the treatment with dimephosphone (54 persons), prednizolone and/or cyclophosphamide (66), dimephosphone combined with prednizolone and/or cyclophosphamide (24) is studied. The most clinical and membranostabilizing effect is achieved in 2—4 weeks that can be used for revealing sensitivity or resistance to dimephosphone and solving the problem of the utility of the further therapy. In the treatment of active glomerulonephritis the combined use of dimephosphone with prednizolone and/or cyclophosphamide has advantages of the isolated use of dimephosphone or immunosupressive therapy since it eliminates the problem of resistance to the drug.